Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study

Autor: Cécile Verite-Goulard, Nadir Cheurfa, Laurence Brugières, Sophie Piperno-Neumann, Laure Saumet, Nathalie Gaspar, Nadège Corradini, Perrine Marec-Berard, Hervé Brisse, Marie-Cécile Le Deley, Françoise Rédini, Claudine Schmitt, Gsf-Geto (Groupe Sarcome Français), Jessy Delaye, Hélène Pacquement, Emmanuelle Bompas, Marie-Pierre Castex, Jean-Claude Gentet, Bob-Valéry Occean, Natacha Entz-Werle, Cyril Lervat, Eric Mascard, Marie-Dominique Tabone, Corine Bouvier, Sfce, Antoine Italiano

Publikováno v: European Journal of Cancer
European Journal of Cancer, Elsevier, 2017, 88, pp.57-66. ⟨10.1016/j.ejca.2017.09.036⟩
European Journal of Cancer, 2017, 88, pp.57-66. ⟨10.1016/j.ejca.2017.09.036⟩

Background In most countries, reference chemotherapy for osteosarcoma is MAP regimen (M = high-dose methotrexate, AP = doxorubicin-cisplatinum). In France, the standard preoperative chemotherapy for children/adolescents combines M and etoposide-ifosf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b208da312db42032cd8ff388934b4d64
https://www.hal.inserm.fr/inserm-01667245

Two novel mutations in the EIF2AK3 gene in children with Wolcott-Rallison syndrome

Autor: Fernando Kok, Farida Jennane, André F. Reis, Thais Della Manna, Roberta Diaz Savoldelli, Bernard Grandchamp, Gilberto Velho, Carolina S. V. Oliveira, Caroline Kannengiesser, Nadir Cheurfa, Claire Oudin

Publikováno v: Pediatric Diabetes. 12:187-191

Wolcott-Rallison syndrome (WRS, OMIM 226980) is a rare autosomal recessive disorder characterized by permanent neonatal diabetes mellitus, epiphyseal dysplasia, and other multisystemic clinical manifestations. We described two novel mutations in the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad41df95fc6bdcfe0a5215c93cacaa33
https://doi.org/10.1111/j.1399-5448.2010.00679.x

The common-866G > A variant in the promoter of UCP2 is associated with decreased risk of coronary artery disease in type 2 diabetic men

Autor: Nadir Cheurfa, Danièle Dubois-Laforgue, Claude Le Feuvre, André F. Reis, Guilherme M. Brenner, Frédéric Fumeron, Clara Bouché, José Timsit, Michel Marre, Gilberto Velho, Daniela A.F. Ferrarezi

Publikováno v: Repositório Institucional da UNIFESP
Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP

OBJECTIVE-Uncoupling protein 2 (UCP2) is a physiological downregulator of reactive oxygen species generation and plays an antiatherogenic role in the vascular wall. A common variant in the UCP2 promoter (-866G>A) modulates mRNA expression, with incre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce420ff8dad37ee6be9cb3552e1d10d5
http://repositorio.unifesp.br/handle/11600/30544

The Gly482Ser polymorphism in the peroxisome proliferator-activated receptor-gamma coactivator-1 gene is associated with hypertension in type 2 diabetic men

Autor: Nadir Cheurfa, André F. Reis, Christine Bellanné-Chantelot, José Timsit, Danièle Dubois-Laforgue, Gilberto Velho

Publikováno v: Diabetologia. 47(11)

Aims/hypothesis. Peroxisome proliferator-activated receptor-γ coactivator-1 (PPARGC1) acts as a cofactor for several nuclear hormone receptors in many tissues and organs implicated in blood pressure regulation. Here, we assessed the association betw

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1e528ff681f6188a1f966dcffd88796
https://pubmed.ncbi.nlm.nih.gov/15599700